Cymabay Therapeutics
CBAY
CBAY was delisted on the 21st of March, 2024.
102 hedge funds and large institutions have $88.7M invested in Cymabay Therapeutics in 2020 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 29 increasing their positions, 32 reducing their positions, and 25 closing their positions.
9% less repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 32
10% less funds holding
Funds holding: 113 → 102 (-11)
21% less capital invested
Capital invested by funds: $112M → $88.7M (-$23.5M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
36% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$4.37M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
+$3.97M |
| 3 |
ECM
Engine Capital Management
New York
|
+$2.11M |
| 4 |
VC
Vivo Capital
Palo Alto,
California
|
+$1.81M |
| 5 |
JP Morgan Chase
New York
|
+$1.28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
-$4.54M |
| 2 |
Morgan Stanley
New York
|
-$3.82M |
| 3 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
-$2.95M |
| 4 |
Millennium Management
New York
|
-$2.41M |
| 5 |
Renaissance Technologies
New York
|
-$833K |
CBAY Hedge Fund Activity: Q1 2020 in Review
102 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q1 2020, worth a combined $88.7M — down 21% from $112M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of CBAY and 16 opened new positions — a net loss of 9 holders — while 32 trimmed existing stakes and 29 added.
The largest buyer was Deutsche Bank, adding an estimated $4.37M. The largest seller was Foresite Capital Management IV, exiting entirely with an estimated $4.54M sold.
- 102 institutional investors held Cymabay Therapeutics (CBAY) as of Q1 2020, down from 113 in Q4 2019.
- Funds reported $88.7M of Cymabay Therapeutics stock for Q1 2020, down 21% quarter-over-quarter.
- 16 funds opened new Cymabay Therapeutics positions in Q1 2020 and 25 closed out, a net change of -9 holders.
- The largest Cymabay Therapeutics buyer in Q1 2020 was Deutsche Bank, an estimated $4.37M added.
- The largest Cymabay Therapeutics seller in Q1 2020 was Foresite Capital Management IV, an estimated $4.54M sold.
Based on aggregated 13F filings for Q1 2020.